European Mind & Metabolism Association

Users' LogIn :
  LOGIN FORM !

support & sponsors welcomed


 Donate !!! How ?
 Do go & click here !
You are here: Home
  • Decrease font size
  • Default font size
  • Increase font size
Serotonin 7 Receptors: New Drugs

One of the most recent research focuses of EMMA is the Serotonin 7 Receptor (INTEREST IS active AND EVER WILL BE) ... with a special focus on new agonist drugs.

5-HT7 receptor has been investigated under the ADHD-sythe project (2009-2012) and also under the NeuroGenMRI project (2011-2014), both led by Dr. W. Adriani for Italy. Both projects now closed. Check the PRECLINICAL goals achieved by "ADHD-sythe" project -or- See the CLINICAL goals of "NeuroGenMRI" project.


 

22-March-2018 | EMMA's people's articles:
Modulatory effects of two novel agonists for serotonin receptor 7 on emotion, motivation and circadian rhythm profiles in mice -BY- Adriani, W., Travaglini, D., Lacivita, E., Saso, L., Leopoldo, M., Laviola, G.
and
Emotional and risk seeking behavior after prepuberal subchronic or adult acute stimulation of 5-HT7-Rs in naples high excitability rats -BY- Ruocco, L.A., Romano, E., Treno, C., lacivita, E., Claudio, A., Gironi-Carnevale, U.A., Travaglini, D., Leopoldo, M

have been cited in:

Downregulation of 5-hydroxytryptamine7receptor in the medial prefrontal cortex ameliorates impulsive actions in animal models of schizophrenia BY Zhang, W., Liu, J., Feng, J., Jia, M., Zhang, G., Wen, X.
Behavioural Brain Research, volume 341, issue , year 2018, pp. 212 - 223

 

 

We announce an upcoming TOPIC (Go!) for Frontiers in Behavioral Neuroscience : it will be guest edited by Dr Walter ADRIANI and Prof Carla PERRONE-CAPANO, and will call for papers (opinions, commentaries, original research investigations, mini- or regular reviews) allowing to focus on the Further Understanding of Serotonin Seven (5-HT7) Receptors’ Neuro-Psycho-Pharmacology (Quick overlook, through the EMMAweb frame)

 


 

 Below, you will find the announcement of relevant papers, published in scientific journals, about the role of 5-HT7 receptors in neuropsychiatry.

Sealed We announce two recent reviews: Sealed  

Di Pilato P, Niso M, Adriani W, Romano E, Travaglini D, Berardi F, Colabufo NA, Perrone R, Laviola G, Lacivita E, Leopoldo M ( 2014 link through DOI ). Selective agonists for serotonin 7 (5-HT7) receptor and their applications in preclinical models: an overview. Reviews in the Neurosciences. Published: Mar 13. 

Romano E, Ruocco LA, Nativio P, Lacivita E, Ajmone-Cat MA, Boatto G, Nieddu M, Tino A, Sadile AG, Minghetti L, Passarelli F, Leopoldo M, Laviola G, Adriani W ( 2014 link through DOI ). Modulatory effects following subchronic stimulation of brain 5-HT7-R system in mice and rats. Reviews in the Neurosciences. Published: Mar 6.

 and, in the same Special Issue:

Gasbarri A, Pompili A ( 2014 link through DOI ). Serotonergic 5-HT7 receptors and cognition. Reviews in the Neurosciences. Published: Feb 1.

 


Serotonin receptor 7, behavioural phenotype and plasticity:

 Eriksson T.M., Holst S., Stan T.L., Hager T., Sjögren B., Ogren S.Ö., Svenningsson P., Stiedl O. (2012 link to DOI). 5-HT1A and 5-HT7 receptor crosstalk in the regulation of emotional memory: implications for effects of selective serotonin reuptake inhibitors. Neuro-pharmacology. 63: 1150-60. Epub 2012 Jul 16.

 Cifariello A., Pompili A., Gasbarri A. (2008 - link to DOI): 5-HT(7) receptors in the modulation of cognitive processes. Behav Brain Res. 195: 171-9.  and  Gasbarri A., Cifariello A., Pompili A., Meneses A. (2008 - link to DOI): Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat. Behav Brain Res. 195: 164-70. 

 Clemett D.A., Cockett M.I., Marsden C.A., Fone K.C. (1998). Antisense oligonucleotide-induced reduction in 5-hydroxy-tryptamine 7 receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function. J Neurochem. 71: 1271-9.

 

  and, also,

Vasefi M.S., Yang K., Li J., Kruk J.S., Heikkila J.J., Jackson M.F., Macdonald J.F., Beazely  M.A. (2013). Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons. Mol Brain. 6: 24. [Epub ahead of print]

 L. Speranza, A. Chambery, M. Di Domenico, M. Crispino, V. Severino, F. Volpicelli, M. Leopoldo, G.C. Bellenchi, U. di Porzio, C. Perrone-Capano (2013 - link to DOI): The serotonin receptor 7 promotes neurite outgrowth via ERK and Cdk5 signaling pathways. Neuropharmacology.

 F. Kobe, D. Guseva, T.P. Jensen, ... and E. Ponimaskin (2013 - link to DOI) 5-HT7R / G12 Signaling Regulates Neuronal Morphology and Function in an Age-Dependent Manner. The Journal of Neuroscience.

 Fan L.L., Zhang Q.J., Liu J., Feng J., Gui Z.H., Ali U., Zhang L., Hou C., Wang T., Hui Y.P., Sun Y.N., Wu Z.H. (2011 link to DOI). In vivo effect of 5-HT7 receptor agonist on pyramidal neurons in medial frontal cortex of normal and 6-hydroxy-dopamine-lesioned rats: an electro-physiological study. Neuroscience. 190: 328-38.

 


|
Serotonin 7 receptors were the topic of an Expert Workshop, held in Rome (IT) on 2013, september 23 (Monday)
  Call for Self-Candidatures (read) - see the Programme

L|  People working on 5-HT7 today !
|

1.       Zekai Halici: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it  

Atatürk University, Faculty of Medicine, Department of Pharmacology, Erzurum, Turkey

|
 

2.       Michael A Beazely: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it  

School of Pharmacy, Waterloo, Ontario, Canada

|
 

3.       Nikiforuk A: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Department of Behavioral Neuroscience & Drug Development, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

|
 

4.       Irvin M. Modlin: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it  

Gastrointestinal Pathobiology Research Group, Yale University School of Medicine, New Haven, Connecticut, USA.

|
 

5.       Waliul I. Khan: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Department of Pathology and Molecular Medicine, Farncombe Family Digestive Health Research Institute, Health Sciences Centre, McMaster University, Hamilton, Ontario, Canada

|
 

6.       Terrón JA: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Zacatenco, Mexico City, Mexico

|
 

7.       Viguier F: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

INSERM U894, CPN, Neuropsychopharmacology, Faculty of Medicine Pierre & Marie Curie, UPMC, Site Pitié-Salpêtrière, Paris, France

|
 

8.       P.B. Hedlund: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Department of Molecular & Cellular Neuroscience, The Scripps Research Institute, La Jolla, California, USA.

|
 

9.       14.&15. Krzysztof Tokarski: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

|
 

10.   Horisawa T: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Suita, Osaka, Japan

|
 

11.   Michael A. Beazely: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

School of Pharmacy, Faculty of Science, University of Waterloo, South Kitchener, Ontario, Canada

|
 

12.   Hitoshi Hashimoto: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan;  Department of Experimental Disease Model, Center for Child Mental Development, United Graduate School of Child Development, Osaka University, Osaka, Japan

|
 

13.   Per Svenningsson: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Laboratory of Translational Neuropharmacology, Center of Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

|
 

16.   Xuejun Deng: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

|
 

17.   Mei Huang: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.

|
 

18.   K. Van Craenenbroeck: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Laboratory of Eukaryotic Gene Expression and Signal Transduction, Department of Physiology, Ghent University, Gent, Belgium

|
 

19.    Bonaventure P.: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., San Diego, California, USA.

| 
 

20.   J. Liu: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it   J. Feng: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Department of Physiology and Pathophysiology, School of Medicine, Xi'an Jiaotong University, Xi'an, PR China

|


Antidepressive action: LuAA21004
A study by Mork et al. used ALZET pumps (Model 2ML1) for 3-day continuous administration of Lu AA21004, a 5-HT receptor antagonist, to evaluate its pharmacological action in rats. The study demonstrated that Lu AA21004 mediates its antidepressive effects via two pharmacological modalities: SERT inhibition and 5-HT receptor modulation. This multimodal activity profile is different from that of current antidepressants, suggesting a unique therapeutic profile.
 J Pharmacol Exp Ther. 2012;340(3):666-75
 
 

 |


Sealed These papers have also been suggested by EMMA's registered users, who freely act as AUTHORS by providing us LINKS, EVENTS and NEWS. To help us, and to signal new articles on this topic, please access to (or set) your own EMMA's account, using the LOGIN FORM !!!



BROWSE here through our ongoing (active) research INTERESTS using "prev" OR "next". Alternatively, jump to PROJECTS and then come back to the latest > use "prev" OR "next" buttons at the footer of each page
 
< Prev   Next >
 

How many online?

Events and Links

Meetings & Congresses

 Index of Congresses ...

 Forthcoming-


the 13th Dresden Symposium on Autoantibodies in September 2017

 



Read more...
 
Debates & Lessons
 User Access:  LOGIN
 
    
Beyond science: philosophy, mind and metabolism:
 
1) Genes, but ...NOT ONLY...

2) Latest hints on innovation: "ALTERNATIVE MEDICINES"

3) The burden of ADHD on modern society (families, health systems).
 
Read more...
 
Societies, Journals (to visit)

Science Societies, Science Journals.

Associations to help people with a psychiatric disease (and their families).
Read more...
 

Sondage

Which of these lotteries would you bet a stake on?